An experimental kidney cancer drug outperformed the standard first-line therapy for patients with metastatic disease who are considered at risk for poorer than average outcomes, according to results of a randomized phase II clinical trial.
from Top Health News – ScienceDaily http://bit.ly/2eWV8XP
from Tumblr http://bit.ly/2fuuObC
No comments:
Post a Comment